Low-Birth Weight and Pre-Term Delivery in Relation to Lopinavir/Ritonavir Use in Pregnancy
Jorge Senise, Reisson Cruz, Ricardo Palacios, Simone Bonafé, Maria Jose Rodrigues Vaz, Ana Paula Lacerda, Abes Ahmed and Adauto Castelo
DOI : 10.3844/ajidsp.2008.209.214
American Journal of Infectious Diseases
Volume 4, Issue 4
The toxic potential of nevirapine in pregnant women with CD4 count over 250 cells mmâ3 and the unsatisfactory efficacy of nelfinavir in patients with baseline Viral Load (VL) over 100,000 copies mLâ1 has prompted the use of Lopinavir/ritonavir (LPV/r) in selected situations. This study aims to assess safety of LPV/r in pregnancy. Medical records from pregnant women receiving LPV/r were retrospectively reviewed. Charts corresponding to twin pregnancy, hypertension and having a lack of data supporting a reliable estimate of Gestational Age (GA) at delivery were excluded. Low Birth Weight (LBW) was defined as less than 2500 g. Pre-Term Delivery (PD), defined as GA at delivery less than 259 days, was estimated using date of Last Menstruation Period (LMP) and obstetrical ultrasound. A total of 64 women were analyzed. LPV/r was used in 46.9% due to virologic failure with other Protease Inhibitors (PIs). LPV/r was used for a mean of 108.8 days. Baseline median CD4+ cell count and HIV-1 RNA were 287 mmâ3 and 31,100 copies mLâ1, respectively and 345 mmâ3 and less than 400 copies mLâ1 at delivery. HIV-1 was not transmitted to any newborn. LBW was observed in 13 (20.3%) and PD in 16 (25%) newborns. Time on LPV/r during pregnancy, maternal age, baseline CD4+ cell count and HIV-1 RNA, GA at initiation of LPV/r, reason for prescribing LPV/r and type of delivery were not associated with PD. Frequencies of LBW and PD were, respectively, 20.3 and 25%. Neither the magnitude nor the timing in pregnancy of LPV/r use was associated with PD.
© 2008 Jorge Senise, Reisson Cruz, Ricardo Palacios, Simone Bonafé, Maria Jose Rodrigues Vaz, Ana Paula Lacerda, Abes Ahmed and Adauto Castelo. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.